Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VYR-206

            Therapeutic Area: Neurology Product Name: VYR-206

            Highest Development Status: Discovery Platform Product Type: Small molecule

            Partner/Sponsor/Collaborator: National Yang-Ming University

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration August 05, 2020

            Details:

            The MOU expresses the intent to develop the bio-distribution information and targeting profile of VYR-206 for diagnosis and monitoring treatment outcomes of neurological disorders.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Small molecule

            Partner/Sponsor/Collaborator: Cerevel Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration July 27, 2020

            Details:

            Cerevel will utilize Cyclica’s Ligand Express® and Ligand Design™ platforms to screen, identify, evaluate and optimize targets to develop neuroscience medicines.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ARMMs based cell and gene therapy

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Bayer HealthCare

            Deal Size: $28.5 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing July 22, 2020

            Details:

            Vesigen’s ARMMs technology enables translation of new modalities such as RNAs and gene-editing complexes into novel treatments for multiple diseases .

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Antibodies

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: Invetx

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership July 16, 2020

            Details:

            Under the terms of the agreement, Twist Biopharma, a division of Twist Bioscience, will use its Twist Antibody Optimization (TAO) platform to engineer and optimize multiple antibodies against important disease targets in animal health.